Michael Richard Feldschuh Buys 3,360 Shares of Daxor Co. (NASDAQ:DXR) Stock

Daxor Co. (NASDAQ:DXR) CEO Michael Richard Feldschuh purchased 3,360 shares of the business’s stock in a transaction dated Monday, March 10th. The shares were purchased at an average price of $7.68 per share, for a total transaction of $25,804.80. Following the acquisition, the chief executive officer now owns 210,852 shares of the company’s stock, valued at approximately $1,619,343.36. The trade was a 1.62 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Daxor Trading Up 4.7 %

NASDAQ:DXR opened at $8.16 on Thursday. The company’s 50 day moving average price is $7.76 and its 200-day moving average price is $8.49. Daxor Co. has a 52 week low of $6.55 and a 52 week high of $10.00.

Institutional Investors Weigh In On Daxor

An institutional investor recently raised its position in Daxor stock. Keyes Stange & Wooten Wealth Management LLC increased its stake in Daxor Co. (NASDAQ:DXR) by 34.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,612 shares of the company’s stock after purchasing an additional 3,771 shares during the quarter. Keyes Stange & Wooten Wealth Management LLC owned 0.30% of Daxor worth $126,000 at the end of the most recent quarter. 1.34% of the stock is currently owned by institutional investors and hedge funds.

Daxor Company Profile

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.